Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Talzenna (talazoparib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BioMarin, Pfizer

Drug class:

PARP inhibitor

Related drugs:

BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
TP53 mutation	HER2 Negative Breast Cancer	TP53 mutation	HER2 Negative Breast Cancer	talazoparib Resistant: B - Late Trials talazoparib Resistant : B	talazoparib Resistant: B - Late Trials talazoparib Resistant : B
BRCA1 mutation	Hormone Receptor Positive Breast Cancer	BRCA1 mutation	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B
BRCA2 mutation	Hormone Receptor Positive Breast Cancer	BRCA2 mutation	Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B	talazoparib Sensitive: B - Late Trials talazoparib Sensitive : B